Your SlideShare is downloading. ×
Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment

150

Published on

ISR identifies and explores the patterns and preferences surrounding the needs, treatments, and side-effects of patients living with autoimmune diseases. This report offers pharmaceutical, biotech, …

ISR identifies and explores the patterns and preferences surrounding the needs, treatments, and side-effects of patients living with autoimmune diseases. This report offers pharmaceutical, biotech, and service provider companies with an opportunity to position their product, enhance clinical development, and improve clinical trial patient recruitment. The report provides value to both commercial and clinical development decision-makers.

The following autoimmune diseases are included:
Celiac disease
Fibromyalgia
Graves’ disease
Hashimoto’s disease
Lupus
Multiple sclerosis
Rheumatoid arthritis
Ulcerative colitis

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
150
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. EW PR EV I Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment Info@ISRreports.com ©2013 Industry Standard Research www.ISRreports.com
  • 2. act with confidence Report Overview ISR identifies and explores the patterns and preferences surrounding the needs, treatments, and side-effects of patients living with autoimmune diseases. This report offers pharmaceutical, biotech, and service provider companies with an opportunity to position their product, enhance clinical development, and improve clinical trial patient recruitment. The report provides value to both commercial and clinical development decision-makers. The following autoimmune diseases are included: • Celiac disease • Fibromyalgia • Graves’ disease • Hashimoto’s disease 208 U.S.-based Respondents • • • • 181 Charts and Graphs Lupus Multiple sclerosis Rheumatoid arthritis Ulcerative colitis 118 Q4, 2013 Pages Publication Date Methodologies: 208 patients in the United States with an autoimmune disease completed a 20-minute web-based quantitative survey conducted by ISR. Major Sections: 1. Executive Summary 2. Unmet Needs of Autoimmune Patients 3. Current Abilities of Patients with Autoimmune Diseases 4. Trends in Autoimmune Diagnosis 5. Patient Care and Physician Interaction 6. Treatment Profiles and Satisfaction Valuable For: • • • • • • Medical Marketing and Advertising Sales Patient Recruitment Clinical Development Brand Management Learn how you can use this report. www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment 2
  • 3. act with confidence What you will learn in this report: • Prevalence of symptoms associated with each disease and the symptoms that cause the most difficulty • Patient satisfaction with current abilities, the occurrence of pain, and how the disease affects everyday life • How a patient’s socio-economic status and level of satisfaction with their condition/ treatment regimen affect their willingness to enroll in a clinical trial • Trends in disease diagnosis • Payment issues with insurance • Patient interactions with physicians (PCPs andSpecialists) and the non-medical individuals they turn to the most for support • And more… How you can use this report: • Design your marketing and advertising plans to account for the current issues and unmet patient needs • Understand patient willingness and hesitations around enrolling in a clinical trial to position enrollment in a positive way • Consider symptom relief, medication side effects, cost, and many other factors when planning for research and development Up next: Full table of contents and sample pages www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment 3
  • 4. act with confidence Table of Contents Full Table of Contents and additional sample pages are available in the full report, which can be downloaded here: http://www.isrreports.com/reportpreview/?report_id=2535&report_name=Autoimmune+Diseases%3A+Curr ent+Treatments%2C+Unmet+Needs%2C+and+Patient+Recruitment www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment 4
  • 5. act with confidence Sample Page: Report Introduction Introduction act with confidence Introduction One Factsway to think about the Russian clinical trial and pharmaceutical environment is to think of the country as a publically traded pharmaceutical company� If you were • Autoimmune prospectus brought on by both natural and hereditary a comleafing through a diseases areor an investor presentation, you would findfactors that cause strong macro fundamentals, historic growth, inconsistent - leading to the pany with the autoimmune system to attack healthy cells in the bodyperformance, and malfunction of normal bodily systems. Russia has many of the same charactersome regulatory uncertainty� In short, • Autoimmune diseases affect 50 million Americans. istics as a mid-stage pharmaceutical company� And, if you take a portfolio theory • There are over 100 different autoimmune diseases with many more that assets approach to investing, you would likely want to invest some portion of your remain unidentified. in Russia� Why? • Autoimmune diseases (as a category) are the leading cause of morbidity for women ↑ in the United States. Macroeconomics: Russia is the world’s 10th largest economy • Women make up about 75% of all autoimmune disease diagnoses. ↑ International recognition: Joined the World Trade Organization (WTO) in 2012 Hypothesis balance sheet: Russia has ~$240B trade surplus from fossil fuel reserves ↑ Positive • ↑ Amongst patients with an$3�9B plan aimed at having 90% consistent patterns Focus: Putin announced autoimmune disease, there are of medicines to be of unmet needs that 2020 locally produced by correlate to patients’ social status, family history, diagnosis pathway, and treatment experience. ↑ Reimbursement structure: Medicines Insurance System (Aug 2012) is to be in place Impact by 2020 that will include a tiered rate of reimbursement, depending on the nature of the illness, and improve access to medications • If the hypothesis holds, pharmaceutical companies will have an opportunity to ↑ Growth: Russian pharmaceutical market has been growing 17% annually since frame their sales, marketing, and advertising plans to address the unmet needs of 2005 patients with an autoimmune disease. There are over $100 billion in healthcare ↑ costs associated with autoimmune are treatment naïve, offering opportunities Untapped potential: Many patients diseases. With data regarding what autoimmune patients want based onrecruitment for clinical trial patient what they have experienced or currently experience, pharmaceutical companies will be able to make more informed decisions about ↓ Uncertainty: Regulatory environment and customs practices are unstable and how to behave in this $100 billion industry. unpredictable • Since completely ridding a patient of an autoimmune disease is not only difficult, but oftenIn 2012 the Worldthe current state of medicine,their list of economies for ↓ Difficult: impossible given Bank ranked Russia 122nd on patients express a need more effective treatment of their persistentChina by ease of doing business, 21 spots below conditions. But what about the current treatments do patients want improved? Some patients may be primarily concerned ↓ Skills: Finding highly qualified healthcare professionals can be difficult with reducing the side effects while another group of patients may be concerned ↓ with lowering the cost of is concerning Protection: IP protection their current treatment regimen. Should this be the case, perhaps patients with one particular autoimmune disease are interested in lower costs, while another group of patients with another autoimmune disease seek a relief of symptoms. • So while it is obvious patients want improved treatment, it is to the benefit of pharmaceutical companies to know what particular groups of patients want in particular areas of treatment. • It may be the case that patients with an autoimmune disorder who see a neurologist as their primary physician are more interested than patients seeing a rheumatologist in signing up for a clinical trial. This type of information leads to money well spent by pharmaceutical companies and those involved in the clinical development process. www.ISRreports.com ©2013 | Russia: Clinical Development Country Profile 7 www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment 5
  • 6. act with confidence Sample Page 2%   6%   10%   17%   8%   Cure fatigue Find a cure/better cure None Other Don't know Current abilities of respondents with an autoimmune disease 1%   0%   2%   4%   4%   6%   11%   6%   3%   9%   7%   14%   11%   11%   19%   7%   10%   14%   34%  J,K   3%   act with confidence Current abilities of respondents with an autoimmune disease General health status General health status is:” (Base=208) “In general, would you say your health “In general, would you say your health is:” (Base=208) Excellent Very good Good Fair Poor Excellent, 3% Poor, 8% Very good, 11% ©Industry Standard Research Fair, 37% Good, 41% Segment differences Segment differences Respondents with celiac disease (29%) are more likely than respondents with Respondents with celiac disease (29%) are more likely than respondents with fibromyalgia (8%) fibromyalgia (8%) or rheumatoid their health to say good”� or rheumatoid arthritis (8%) to sayarthritis (8%) is “verytheir health is “very good”.   CONDITION   Excellent Very Good Good Excellent Very Good Good Fair Poor   Total   Total (N=190)   (N=190) 3%   11%   41%   3% 11%   Condition   Celiac  Disease   Fibromyalgia   MS   Fibromyalgia Celiac Disease (N=85)   (N=21)   (N=27)   A   B   (N=85) C   (N=21) 10%   0%   4%   B A 29%  B,D   8%   15%   29%  10% 41%   26%   0% 29% B,D 8% RA   RA MS (N=74)   (N=74) (N=27) D   3%   D C 8%   4% 45%   3% 15% 8% 41% 29% 41% 26% www.isrreports.com   © 2013|   R eport   T itle   g oes   h ere.   U se   t he   r uler   h andles   t o   a lign52   37% 29% 40% 48% 8% 5% 11% 7% 45%   34% 11% ©Industry Standard Research www.ISRreports.com ©2013 | Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment 51 www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com). 6
  • 7. act with confidence Sample Page Full Table of Contents and additional sample pages are available in the full report, which can be downloaded here: http://www.isrreports.com/reportpreview/?report_id=2535&report_name=Autoimmune+Diseases%3A+Curr ent+Treatments%2C+Unmet+Needs%2C+and+Patient+Recruitment www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment 7
  • 8. act with confidence Ordering Information For pricing and ordering information, please visit our website: http:// www.isrreports.com/report-preview/?report_id=2535&report_name=Auto immune+Diseases%3A+Current+Treatments%2C+Unmet+Needs%2C+and +Patient+Recruitment About Industry Standard Research Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.    For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports. www.ISRreports.com ©2013 | Preview of: Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment 8
  • 9. The ISR Difference act with confidence Custom-quality syndicated market research www.ISRreports.com ISR's Reports vs. The Common Syndicated Report How confident are you? Research methods Mostly primary research; always appropriate for the topic vs. vs. One size fits all; usually publically available data Data Collection ISR's proprietary data collection tools and channels support fast, high quality data collection vs. Struggle to recruit the right targets and enough of them Respondents Sophisticated screening ensures genuine decision-makers vs. Undisclosed methodologies and respondent demographics Sample Sizes Robust sample sizes that instill confidence vs. Often insufficient industry representation that leaves you defending results Analysts Decades of experience means more insights that are immediately usable vs. vs. Junior analysts capable of reporting numbers www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 10

×